pharmaphorum December 18, 2025
One criticism of injectable weight-loss drugs is that people tend to put the pounds back on after they stop taking them. Could a new generation of oral therapies address that issue?
One of the companies developing oral GLP-1 agonist therapies for obesity, Eli Lilly, has offered new data to suggest that this might be the case.
In the ATTAIN-MAINTAIN study of its orforglipron candidate, switching to the drug after 72 months of injectable treatment with Lilly’s Zepbound (tirzepatide) or Novo Nordisk’s Wegovy (semaglutide) allowed patients to keep the weight off.
According to Lilly, it is the first study to look at oral maintenance therapy with a GLP-1 drug in this way, and could provide a way to facilitate long-term weight-loss...
Today's Sponsors
Today's Sponsor